The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|August 2, 2022
Rheumatoid Arthritis Quiz: Disease Activity Score
Author(s)Ingrid Torjesen
Assessing disease activity is an important part of a treat-to-target strategy. How much do you know about the different approaches? Take this quiz to find out.
Advertisement
Which of the following is not one of the American College of Rheumatology’s preferred measures for assessing disease activity in routine clinical practice?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement